Karyopharm Therapeutics Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 85 WELLS AVENUE, NEWTON, MA, 02459
Mailing Address 85 WELLS AVENUE, NEWTON, MA, 02459
Phone 617-658-0600
Fiscal Year End 1231
EIN 263931704
Financial Overview
FY2025
-$76.42M
Net Income
$164.42M
Total Assets
$401.34M
Total Liabilities
-$16.66M
Stockholders' Equity
$62.48M
Cash & Equivalents
$-9.41
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | February 13, 2026 | View on SEC |
| 8-K Current report of material events | February 12, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 12, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 10, 2026 | View on SEC |
| 4 Insider stock transaction report | February 9, 2026 | View on SEC |
| 4 Insider stock transaction report | February 4, 2026 | View on SEC |
| 4 Insider stock transaction report | February 3, 2026 | View on SEC |
| 4 Insider stock transaction report | February 3, 2026 | View on SEC |
| 4 Insider stock transaction report | February 3, 2026 | View on SEC |
| 4 Insider stock transaction report | February 3, 2026 | View on SEC |
Annual Reports
10-K February 13, 2026
- Commercial-stage biopharmaceutical company with flagship product XPOVIO® approved for multiple myeloma and diffuse large B-cell lymphoma.
- Robust commercial activity, significant pipeline progression, and active financial management including non-dilutive financing.
Insider Trading
SELL 2 insiders
3 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.